Oryzon to Present its LSD1 programs in Acute Leukemias and in Neurodegenerative disorders at the GTC’s 3rd Epigenetics in Drug Discovery conference in Boston
Barcelona, May 2th, 2013.Oryzon announced today that Dr. Tamara Maes will present the latest advances of its LSD1 program in hematological malignancies at GTC’s 3rd Epigenetics in Drug Discovery conference in the session Drug Discovery in Epigenetics: on May 8-10 at the Hyatt Regency in Boston, MA.
